Arbutus Biopharma Corp Annual Report - How They Did This Year

Thinking about Arbutus Biopharma (ABUS on Nasdaq)? They're based in Warminster, PA. Let's review their 2025 annual report. We'll skip the jargon and keep it simple.

What Arbutus Biopharma Does

Arbutus develops drugs for chronic hepatitis B infection (HBV). HBV is a serious liver disease. A virus causes it. It can lead to severe liver damage, cirrhosis, and liver cancer. Their goal is to prevent complications. They want to reduce the virus in patients. They aim to find better treatments. These treatments should improve long-term health and lower costs. Current treatments often only suppress the virus. They rarely offer a cure. Arbutus wants to improve these.

Their main drug candidates are imdusiran (AB-729) and AB-101. Imdusiran is an RNA interference (RNAi) drug. It interferes with genetic material to suppress the virus. AB-101 is an oral treatment. It aims to boost the immune system to fight the virus. Imdusiran is in early clinical trials (Phase 1 and 2a).

How Their Money Situation Looks (Financial Health)

Arbutus is a "smaller reporting company" and a "non-accelerated filer." This means they are not a giant company like Apple or Pfizer. They follow different, simpler reporting rules. This is due to their smaller total share value and fewer shares available to trade.

As of June 30, 2025, the company's total value was about $472 million. This was based on a $3.09 stock price per share. They had about 195.5 million shares available as of March 18, 2026.

Now, for the tough news. Arbutus has been losing money from operations almost every year. They don't expect to make a profit soon. They also don't sell any drugs yet. This means they have no income from drug sales. They constantly spend cash to fund research and operations.

However, there's a big positive cash development! In March 2026, Arbutus and Genevant Sciences settled with Moderna. This deal includes a guaranteed one-time payment of $950 million. They expect this by July 8, 2026. Arbutus's direct share, after legal costs, is 20%, about $190 million. Arbutus also owns about 16% of Genevant Sciences. This means they benefit from Genevant's share ($760 million). This adds another $121.6 million to Arbutus's cash. So, a big estimated total cash boost of $311.6 million is coming! They are even thinking about giving some money back to shareholders. This could happen in late 2026, perhaps as a special payout or by buying back shares.

Moderna might pay an additional $1.3 billion. This depends on Arbutus and Genevant winning a specific appeal. This appeal concerns whether certain patents are valid.

Arbutus made big changes in 2024 and 2025 to manage their spending. They cut their staff by 40% in 2024 and another 57% in early 2025. This greatly reduced their staff costs. They also stopped all new drug discovery. They closed their headquarters. They ended their own scientific research. This helps them focus money on their main drug programs. These tough decisions led to $12.9 million in reorganization costs in 2025. But they also greatly reduced how much cash they spent compared to 2024.

Even with the Moderna settlement, they will likely need to raise a lot more money. This is to keep going long-term. Drug development costs hundreds of millions for one drug. If they sell more shares, it could mean more shares issued, reducing your ownership percentage. If they cannot get more money, they might slow or stop their programs.

They also have a deal with Alnylam Pharmaceuticals for ONPATTRO™. This could bring in some money from royalties.

Big Things Happening & What's Next

Arbutus's story now largely involves patent lawsuits and settlements.

• Moderna Settlement: This is a huge development. They settled their lawsuit with Moderna. They are getting a guaranteed $950 million payment (shared with Genevant) by July 2026. Arbutus's direct share is 20%, about $190 million after legal costs. They also benefit from their 16% ownership share in Genevant. This brings their total estimated benefit to about $311.6 million. An additional $1.3 billion is possible if they win a specific appeal. This would further strengthen their finances. It could also mean more money back to shareholders.
• Pfizer/BioNTech Lawsuit: They are still suing Pfizer/BioNTech. This is for using their patents without permission. It relates to the LNP technology in COVID-19 vaccines. In September 2025, the court ruled on key legal terms. Arbutus sees this as favorable. This is good news. It strengthens their case for damages or settlements.
• They are also suing the U.S. government for using their patents without permission. This is another ongoing legal battle.

On the drug development side, they are still early. But they have promising updates:

• Imdusiran (AB-729): This RNAi drug for HBV has been tested in over 200 patients. These were early clinical trials (Phase 1 and 2a). Results show it can greatly reduce the virus and its markers (like HBsAg). It has even led to a "functional cure" in some patients. This means the virus is undetectable. The patient is off treatment. In total, 10 patients have achieved a functional cure in different studies. Almost half of patients in some Phase 2a trials achieved a functional cure. Or they stayed off standard therapy for a long time. It has also been generally safe and patients tolerated it well.
• AB-101: This is another HBV drug. It's an oral treatment designed to boost the immune system.

Major Organizational Changes: Arbutus had a big reorganization in 2024 and 2025. This was to focus efforts and cut costs. They made huge staff cuts: 40% in 2024 and another 57% in early 2025. They hired new leaders (CEO, CFO, and Board members). They closed their headquarters. They stopped early-stage research. This helps them focus on their main drugs. They also launched a new Scientific Advisory Board in June 2025. HBV experts are on this board to guide their plans.

What Could Go Wrong (Risks for Investors)

Investing in Arbutus has significant risks, even with the good news:

• Lawsuit Uncertainty: The Moderna settlement is great. But the Pfizer/BioNTech lawsuit is ongoing and expensive. They might not win. Even if they win, damages awarded are uncertain. These could also be appealed. The additional $1.3 billion from Moderna depends on winning a specific patent appeal. So, it's not guaranteed. It may also take years to resolve.
• Clinical Hold on AB-101: The FDA paused AB-101's development with a "clinical hold." This usually happens due to safety concerns or not enough data. Resolving this could take much time and money. It requires more studies or data. The FDA might not lift the hold. This is a big setback for AB-101. This could delay or even end its development.
• Early Stage Drug Development is Risky: Their products are still in development. Clinical trials are very expensive, time-consuming, and difficult. Many drugs fail. Early positive results, like with imdusiran, don't promise success in later, larger Phase 3 trials. Many drugs fail or don't get approved. This happens due to unexpected side effects, not working well in more people, or trouble finding enough patients.
• Need for More Cash (Long-term): The Moderna settlement helps a lot. But developing drugs to market is very expensive. It often costs hundreds of millions to billions of dollars. They will likely need more money for late-stage trials. They also need cash to get ready to sell them. If they sell more shares, your investment could be worth less per share (more shares issued, reducing your ownership percentage). If they can't raise money, their programs could stop or be dropped.
• No Profits Yet: They have been losing money. They don't expect to be profitable or sell products soon. This is common for a biotech company. It means they are far from making their own money. They rely on outside money or licensing deals.
• Dependence on Others: They rely on other companies. These companies manufacture their drugs and run clinical trials. They also get some money from licensing deals (like with Alnylam). If these partners fail, have manufacturing problems, or end deals, this could hurt Arbutus.
• Intellectual Property Challenges: Competitors can challenge their patents. Courts can also find them invalid. Some have been found invalid before. This could weaken their standing against rivals. It could also reduce money from licensing or damages from patent lawsuits.
• Regulatory Hurdles: Even if a drug gets approved, it faces strict ongoing rules. These come from health regulators like the FDA. Also, getting insurance companies to cover and pay enough for new drugs can be hard. This affects sales and how widely the drug is used.

This company is for investors okay with higher risk. They hope for a big reward if drugs succeed and lawsuits go their way. The Moderna settlement provides a much-needed cash buffer. But the path ahead for their drugs is still long and unsure.